Jesse Boehm
@boehmjesse.bsky.social
Chief Science Officer, Break Through Cancer; Principal Investigator, Koch Institute, MIT - boehmlab.org
Reposted by Jesse Boehm
Both chambers of Congress have now passed the FY26 minibus with NIH provisions. The President will sign.
(1) $48.7 billion for NIH
(2) Full IDC recovery
(3) No more multi-year funding
(4) No NIH reorganization, maintaining the current IC structure.
(1) $48.7 billion for NIH
(2) Full IDC recovery
(3) No more multi-year funding
(4) No NIH reorganization, maintaining the current IC structure.
February 3, 2026 at 7:48 PM
Both chambers of Congress have now passed the FY26 minibus with NIH provisions. The President will sign.
(1) $48.7 billion for NIH
(2) Full IDC recovery
(3) No more multi-year funding
(4) No NIH reorganization, maintaining the current IC structure.
(1) $48.7 billion for NIH
(2) Full IDC recovery
(3) No more multi-year funding
(4) No NIH reorganization, maintaining the current IC structure.
Reposted by Jesse Boehm
We are excited to join The Mark Foundation for Cancer Research, Lustgarten Foundation, Break Through Cancer, and Tina's Wish in a collaboration to solve the critical problem of early detection and diagnosis for some of the world’s deadliest cancers. buff.ly/EAA0knn
February 3, 2026 at 8:06 PM
We are excited to join The Mark Foundation for Cancer Research, Lustgarten Foundation, Break Through Cancer, and Tina's Wish in a collaboration to solve the critical problem of early detection and diagnosis for some of the world’s deadliest cancers. buff.ly/EAA0knn
Reposted by Jesse Boehm
Long time off this platform.. excited to be back to share that I have been elected President of the @thesfpm.bsky.social alongside @boehmjesse.bsky.social. This community has been a true home for those of us for whom patient-derived models and functional testing belong at the center of cancer care/n
December 13, 2025 at 9:51 PM
Long time off this platform.. excited to be back to share that I have been elected President of the @thesfpm.bsky.social alongside @boehmjesse.bsky.social. This community has been a true home for those of us for whom patient-derived models and functional testing belong at the center of cancer care/n
Reposted by Jesse Boehm
Great to hear Iain Foulkes join @break-cancer.bsky.social's @boehmjesse.bsky.social, @su2c.bsky.social's Julian Adams & NUT Carcinoma Alliance's Maddie Musselman at @milkeninstitute.org #MIHealthSummit to discuss how global collaboration can drive innovation in cancer research #CancerGrandChallenges
November 7, 2025 at 3:49 PM
Great to hear Iain Foulkes join @break-cancer.bsky.social's @boehmjesse.bsky.social, @su2c.bsky.social's Julian Adams & NUT Carcinoma Alliance's Maddie Musselman at @milkeninstitute.org #MIHealthSummit to discuss how global collaboration can drive innovation in cancer research #CancerGrandChallenges
It was a great discussion! There has never before been so much opportunity to work together to solve the major challenges of our field.
Dr. Julian Adams, President and CEO of @su2c.bsky.social, is at the @milkeninstitute.org today discussing innovations in #EarlyDetection and equitable cancer care. Panelists include @boehmjesse.bsky.social from @break-cancer.bsky.social, Ian Foulkes from @cancerresearchuk.org, and Maddie Musselman
November 6, 2025 at 10:46 PM
It was a great discussion! There has never before been so much opportunity to work together to solve the major challenges of our field.
We are very proud of our Accelerating GBM Therapies TeamLab for this outstanding, potentially field changing work. We must sample continuously to understand hidden, temporal responses to therapy. Even in the brain.
Researchers have applied serial biopsies to safely monitor glioblastoma progression and responses to immunotherapy in two patients, capturing details that are invisible to standard-of-care MRI.
Learn more in #ScienceTranslationalMedicine: https://scim.ag/46Id31J
Learn more in #ScienceTranslationalMedicine: https://scim.ag/46Id31J
Now you see me; now you don’t
Multiomics on serial glioblastoma biopsies can enable differentiation of pseudoprogression from true tumor progression (see Ling et al.).
scim.ag
October 9, 2025 at 3:20 PM
We are very proud of our Accelerating GBM Therapies TeamLab for this outstanding, potentially field changing work. We must sample continuously to understand hidden, temporal responses to therapy. Even in the brain.
Reposted by Jesse Boehm
Excited to get this out there as we go through revisions. These findings have changed how I think about KIAA1549-BRAF of pediatric gliomas, and all other fusions, completely.
The fusion partner is important, necessary and engenders novel vulnerabilities that can be therapeutically targeted.
The fusion partner is important, necessary and engenders novel vulnerabilities that can be therapeutically targeted.
Together with @glyco.me, @bandolab.bsky.social and teams, we recently uncovered a link between pediatric brain tumors, POMT1/2 enzymes and KIAA1549 - full story in the preprint below:
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
O-mannosylation and protein maturation check-points represent therapeutic opportunities in BRAF fusion protein oncogenesis
Fusions between protein-coding genes are common oncogenic drivers across cancers, typically pairing a proto-oncogene with partner that does not independently drive cancer. In all therapeutically actio...
www.biorxiv.org
August 23, 2025 at 9:31 PM
Excited to get this out there as we go through revisions. These findings have changed how I think about KIAA1549-BRAF of pediatric gliomas, and all other fusions, completely.
The fusion partner is important, necessary and engenders novel vulnerabilities that can be therapeutically targeted.
The fusion partner is important, necessary and engenders novel vulnerabilities that can be therapeutically targeted.
Reposted by Jesse Boehm
Be sure to catch Jesse Boehm @boehmjesse.bsky.social in the Tumoroids, Organoids, and Cell Culture session at #AACR25! He’ll present how patient-derived cancer models are shaping research on rare and understudied cancers.
🔗 www.abstractsonline.com/pp8/#!/20273...
🔗 www.abstractsonline.com/pp8/#!/20273...
April 28, 2025 at 4:06 PM
Be sure to catch Jesse Boehm @boehmjesse.bsky.social in the Tumoroids, Organoids, and Cell Culture session at #AACR25! He’ll present how patient-derived cancer models are shaping research on rare and understudied cancers.
🔗 www.abstractsonline.com/pp8/#!/20273...
🔗 www.abstractsonline.com/pp8/#!/20273...
Reposted by Jesse Boehm
Today marks the beginning of OpenRxiv, which replaces bioRxiv and medRxiv, the world's largest preprint platform for life and medical science
openrxiv.org/introducing-...
@openrxiv.bsky.social
openrxiv.org/introducing-...
@openrxiv.bsky.social
March 11, 2025 at 2:55 PM
Today marks the beginning of OpenRxiv, which replaces bioRxiv and medRxiv, the world's largest preprint platform for life and medical science
openrxiv.org/introducing-...
@openrxiv.bsky.social
openrxiv.org/introducing-...
@openrxiv.bsky.social
Reposted by Jesse Boehm
Research support for rare diseases, which cumulatively affect ~30 million Americans, is primarily derived from NIH.
Such work is exemplified by Prof Anna Greka @broadinstitute.org in a new Ground Truths podcast.
Open-access, w/ transcript, video, no ads
erictopol.substack.com/p/anna-greka...
Such work is exemplified by Prof Anna Greka @broadinstitute.org in a new Ground Truths podcast.
Open-access, w/ transcript, video, no ads
erictopol.substack.com/p/anna-greka...
Anna Greka: Molecular Sleuthing for Rare Diseases
Listen now | Finding the Mechanisms and the Basis for Potential Cures
erictopol.substack.com
March 9, 2025 at 2:29 PM
Research support for rare diseases, which cumulatively affect ~30 million Americans, is primarily derived from NIH.
Such work is exemplified by Prof Anna Greka @broadinstitute.org in a new Ground Truths podcast.
Open-access, w/ transcript, video, no ads
erictopol.substack.com/p/anna-greka...
Such work is exemplified by Prof Anna Greka @broadinstitute.org in a new Ground Truths podcast.
Open-access, w/ transcript, video, no ads
erictopol.substack.com/p/anna-greka...
Reposted by Jesse Boehm
3 points of progress vs pancreatic cancer!
1. Neoantigen vaccines
www.nature.com/articles/s41...
2. KRAS drugs
www.wsj.com/health/healt...
3. Early diagnosis www.science.org/doi/10.1126/...
1. Neoantigen vaccines
www.nature.com/articles/s41...
2. KRAS drugs
www.wsj.com/health/healt...
3. Early diagnosis www.science.org/doi/10.1126/...
March 1, 2025 at 3:26 PM
3 points of progress vs pancreatic cancer!
1. Neoantigen vaccines
www.nature.com/articles/s41...
2. KRAS drugs
www.wsj.com/health/healt...
3. Early diagnosis www.science.org/doi/10.1126/...
1. Neoantigen vaccines
www.nature.com/articles/s41...
2. KRAS drugs
www.wsj.com/health/healt...
3. Early diagnosis www.science.org/doi/10.1126/...
Reposted by Jesse Boehm
Francis Collins, the NIH Director for 12 years, led the Human Genome Project and other NIH efforts for 32 years, resigned today. Key words from his resignation letter
www.nytimes.com/2025/03/01/u...
www.nytimes.com/2025/03/01/u...
March 1, 2025 at 6:07 PM
Francis Collins, the NIH Director for 12 years, led the Human Genome Project and other NIH efforts for 32 years, resigned today. Key words from his resignation letter
www.nytimes.com/2025/03/01/u...
www.nytimes.com/2025/03/01/u...
Reposted by Jesse Boehm
“The rare tumor space is an example of where we should think hard about the quality data that we have and how we can help inform future treatments,” @danafarber.bsky.social’s Suzanne George, MD, shared at #RareDiseaseSummit 2025.
February 26, 2025 at 3:00 PM
“The rare tumor space is an example of where we should think hard about the quality data that we have and how we can help inform future treatments,” @danafarber.bsky.social’s Suzanne George, MD, shared at #RareDiseaseSummit 2025.
Reposted by Jesse Boehm
Inexplicably, US administration has launched an unprecedented assault on science, on research institutions & on vital international organizations & initiatives.
An assault on science anywhere is an assault on science everywhere; the global community must unite
🧪
www.nature.com/articles/d41...
An assault on science anywhere is an assault on science everywhere; the global community must unite
🧪
www.nature.com/articles/d41...
Trump 2.0: an assault on science anywhere is an assault on science everywhere
US President Donald Trump is taking a wrecking ball to science and to international institutions. The global research community must take a stand against these attacks.
www.nature.com
February 25, 2025 at 7:48 PM
Inexplicably, US administration has launched an unprecedented assault on science, on research institutions & on vital international organizations & initiatives.
An assault on science anywhere is an assault on science everywhere; the global community must unite
🧪
www.nature.com/articles/d41...
An assault on science anywhere is an assault on science everywhere; the global community must unite
🧪
www.nature.com/articles/d41...
Excited to be speaking this Tuesday, Feb. 25 at #RareDiseaseSummit 2025, @GlobeEvent’s inaugural summit focused on innovation and advocacy in rare disease, “From Bench to Bedside: Rare Cancer Innovations.” Sign up to join in person or virtually: @bostonglobe.com rarediseasesummit2025.splashthat.com
February 22, 2025 at 8:03 PM
Excited to be speaking this Tuesday, Feb. 25 at #RareDiseaseSummit 2025, @GlobeEvent’s inaugural summit focused on innovation and advocacy in rare disease, “From Bench to Bedside: Rare Cancer Innovations.” Sign up to join in person or virtually: @bostonglobe.com rarediseasesummit2025.splashthat.com
Reposted by Jesse Boehm
Exciting new synthetic lethal target emerging from #depmap data 🧪🧬
Frequent passenger mutations in genes involved in mRNA quality control lead to a dependency on PELO-HBS1L
Congratulations to the DepMap team! @vazquezf.bsky.social
#depmap #cancertarget #syntheticlethal
Frequent passenger mutations in genes involved in mRNA quality control lead to a dependency on PELO-HBS1L
Congratulations to the DepMap team! @vazquezf.bsky.social
#depmap #cancertarget #syntheticlethal
SKI complex loss renders 9p21.3-deleted or MSI-H cancers dependent on PELO - Nature
Analysis of large-scale CRISPR screening data, combined with experiments in patient-derived tumour organoid models, identifies PELO as a potential therapeutic target in chromosomal 9p21.3-deleted canc...
www.nature.com
February 5, 2025 at 10:01 PM
Exciting new synthetic lethal target emerging from #depmap data 🧪🧬
Frequent passenger mutations in genes involved in mRNA quality control lead to a dependency on PELO-HBS1L
Congratulations to the DepMap team! @vazquezf.bsky.social
#depmap #cancertarget #syntheticlethal
Frequent passenger mutations in genes involved in mRNA quality control lead to a dependency on PELO-HBS1L
Congratulations to the DepMap team! @vazquezf.bsky.social
#depmap #cancertarget #syntheticlethal
Reposted by Jesse Boehm
(1/3) Excited to share our latest work using
@depmap.org to uncover a new synthetic lethality in two distinct patient populations!
We found that SKI complex inactivation through two independent genomic alterations creates a dependency on PELO
#CancerResearch #SyntheticLethality #Genomics #DepMap
@depmap.org to uncover a new synthetic lethality in two distinct patient populations!
We found that SKI complex inactivation through two independent genomic alterations creates a dependency on PELO
#CancerResearch #SyntheticLethality #Genomics #DepMap
SKI complex loss renders 9p21.3-deleted or MSI-H cancers dependent on PELO - Nature
Analysis of large-scale CRISPR screening data, combined with experiments in patient-derived tumour organoid models, identifies PELO as a potential therapeutic target in chromosomal 9p21.3-deleted canc...
nature.com
February 6, 2025 at 1:07 PM
(1/3) Excited to share our latest work using
@depmap.org to uncover a new synthetic lethality in two distinct patient populations!
We found that SKI complex inactivation through two independent genomic alterations creates a dependency on PELO
#CancerResearch #SyntheticLethality #Genomics #DepMap
@depmap.org to uncover a new synthetic lethality in two distinct patient populations!
We found that SKI complex inactivation through two independent genomic alterations creates a dependency on PELO
#CancerResearch #SyntheticLethality #Genomics #DepMap
Reposted by Jesse Boehm
A full attack on US science means the red & blue lines will soon cross. Scientists just want science to progress to help society. This administration - and "Pres Musk" - is telling us they don't need/want US science. We will see many of our great ideas and innovation will go to China and elsewhere
February 8, 2025 at 3:42 PM
A full attack on US science means the red & blue lines will soon cross. Scientists just want science to progress to help society. This administration - and "Pres Musk" - is telling us they don't need/want US science. We will see many of our great ideas and innovation will go to China and elsewhere
Reposted by Jesse Boehm
Breaking news: The Trump administration cut billions in biomedical funding. Researchers say it imperils work on cancer and other illnesses.
NIH cuts billions of dollars in biomedical funding, effective immediately
The move halts a large slice of money for most universities and research institutions virtually overnight, imperiling vital research in everything from cancer to heart disease.
www.washingtonpost.com
February 8, 2025 at 5:01 PM
Breaking news: The Trump administration cut billions in biomedical funding. Researchers say it imperils work on cancer and other illnesses.
Reposted by Jesse Boehm
The National Institutes of Health plans to severely cut the percentage of its grant money that can be used for overhead costs rather than research.
NIH slashes overhead payments for research, sparking outrage
Move to cut indirect cost rate to 15% could cost universities billions of dollars
scim.ag
February 8, 2025 at 2:50 AM
The National Institutes of Health plans to severely cut the percentage of its grant money that can be used for overhead costs rather than research.
Reposted by Jesse Boehm
This will kill science in the US. This is how China wins. Why is this not on the news? Why are people not more upset about this?
grants.nih.gov/grants/guide...
grants.nih.gov/grants/guide...
NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates NOT-OD-25-068. OD
grants.nih.gov
February 8, 2025 at 1:43 AM
This will kill science in the US. This is how China wins. Why is this not on the news? Why are people not more upset about this?
grants.nih.gov/grants/guide...
grants.nih.gov/grants/guide...
This!
#COMMENT 🐶 🐱
Pet dogs with cancer facilitate comparative oncology, enhancing translational research. In this Comment, Lenz & Atherton highlight successes and emphasize the need for broader application to improve human cancer treatments.
📖 👇
https://bit.ly/414hi...
Pet dogs with cancer facilitate comparative oncology, enhancing translational research. In this Comment, Lenz & Atherton highlight successes and emphasize the need for broader application to improve human cancer treatments.
📖 👇
https://bit.ly/414hi...
Maximizing the dual benefit of pet dogs in cancer trials - Nature Reviews Cancer
Pet dogs with cancer facilitate comparative oncology, enhancing translational research. In this Comment, Lenz and Atherton highlight comparative oncology successes, emphasizing the need for broader application of findings from canine studies to improve human cancer treatments.
bit.ly
February 7, 2025 at 8:29 PM
This!
Reposted by Jesse Boehm
Thank you #AACR for your strong support of #cancer researchers and the people who do that work!
www.aacr.org/about-the-aa...
www.aacr.org/about-the-aa...
AACR Statement on the New Administration’s Recent Executive Orders and Policy Proposals
The American Association for Cancer Research (AACR) is increasingly concerned about the numerous executive orders and policy proposals that the new administration has issued during the first two weeks...
www.aacr.org
February 5, 2025 at 4:47 AM
Thank you #AACR for your strong support of #cancer researchers and the people who do that work!
www.aacr.org/about-the-aa...
www.aacr.org/about-the-aa...
It's time to tackle rare cancers together - both a scientific opportunity and a moral imperative! I've shared a few brief thoughts in the Trends in Cancer opinions perspective on this topic - out now online www.cell.com/trends/cance...
Think zebras: challenges and opportunities for treating rare cancers
The adage goes, ‘When you hear hoofbeats, think of horses, not zebras’. However, placing
less emphasis on ‘zebras’ – both in the clinical and research space – can prevent
many rare cancers from being ...
www.cell.com
January 29, 2025 at 10:22 PM
It's time to tackle rare cancers together - both a scientific opportunity and a moral imperative! I've shared a few brief thoughts in the Trends in Cancer opinions perspective on this topic - out now online www.cell.com/trends/cance...
Reposted by Jesse Boehm
So, we teamed up with Anne and Paul’s lab, along with Calvin Jan at Calico, with the aim of building an accessible & unbiased high-content cell profiling platform that could be applied to genome-scale CRISPR screens (Project PERISCOPE).
January 27, 2025 at 6:23 PM
So, we teamed up with Anne and Paul’s lab, along with Calvin Jan at Calico, with the aim of building an accessible & unbiased high-content cell profiling platform that could be applied to genome-scale CRISPR screens (Project PERISCOPE).